Results 121 to 130 of about 12,993 (261)

Stakeholders' perspectives on integrating point‐of‐care diagnostics into forensic death investigations in South Africa

Journal of Forensic Sciences, EarlyView.
Abstract Unnatural and unexplained deaths present critical challenges to the criminal justice, medico‐legal, and public health systems. This study explored forensic professionals' perspectives on the integration of point‐of‐care (POC) diagnostics into unnatural death investigations in South Africa.
Sebueng Ramatsokotla, Bathabile Soul, Kuhlula Maluleke, Lucinda Evert, Stefan Jansen van Vurren, Bettina Chale‐Matsau, Susan Mabotja, Evans Duah, Tivani Mashamba‐Thompson   +8 more
wiley   +1 more source

Trajectories of medication for opioid use disorder and their impact on HIV testing among people who inject drugs in India: A longitudinal assessment of clinic‐based data

Addiction, Volume 120, Issue 4, Page 745-755, April 2025.
Abstract Aims The aim of this study was to identify longitudinal trajectories of medication for opioid use disorder (MOUD) use throughout 1 year following MOUD initiation and to examine the association of trajectory membership with HIV testing among people who inject drugs in India.
Allison M. McFall, Lakshmi Ganapathi, Mihili P. Gunaratne, Aylur K. Srikrishnan, Conjeevaram K. Vasudevan, Santhanam Anand, Sunil S. Solomon, Shruti H. Mehta, Gregory M. Lucas   +8 more
wiley   +1 more source

HCV medication affected by Genetic Variations in Host factors

Research in Molecular Medicine, 2017
Although standard treatments are nearly life-saving in hepatitis C patients, all patients equally don’t respond to such medications. To achieve a favorable therapeutic response in all patients, medications might alter between individuals based on ...
Maryam Karkhane, Abdolrazagh Marzban, Hamed Esmaeil Lashgarian, Mohammad Reza Zali   +3 more
doaj  

High sustained virologic response rates, regardless of race or socioeconomic class, in patients treated with chronic hepatitis C in community practice using a specialized pharmacy team. [PDF]

Medicine (Baltimore), 2023
Kuwelker S, Tsai E, Kuo L, Kim J, Van Frank T, Mitchell R, Ramirez R, Guerrero R, Hanysak B, Landaverde C, Rodas F, Lawitz E, Basra T, Nguyen H, Christensen K, Vaughn C, Hinojosa K, Olvera N, Caraballo-Gonzalez E, Pham E, Pedicone LD, Poordad F.   +21 more
europepmc   +1 more source

Temporal Association Between COVID‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis

Alimentary Pharmacology &Therapeutics, EarlyView.
In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi, Allison Carroll, Vy H. Nguyen, Megan Michta, Xuan Q. Zhang, Young‐Suk Lim, Raymond T. Chung   +6 more
wiley   +1 more source

Brain viral reservoir seeding and neurological metabolic dysregulation in early‐life immunodeficiency virus infection

Brain Pathology, EarlyView.
Brain viral reservoirs were undetectable in neonatal SIV during the first 3 days post infection; antiretroviral therapy (ART) at 3 dpi prevented brain reservoir seeding and normalized metabolic function, highlighting the necessity of very early treatment to protect the developing CNS.
Li Ma, Robert Blair, Yao‐Zhong Liu, Xiaolei Wang, Eunice Vincent, Christopher Yu, Lara A. Doyle‐Meyers, Cissy Zhang, Ahmad Saied, Anne Le, Ronald S. Veazey, Qigui Yu, Huanbin Xu   +12 more
wiley   +1 more source

Splenic Marginal Zone Lymphoma as a Vascular-Appearing Mass in a Patient With Sustained Virologic Response to Hepatitis C Therapy. [PDF]

Am J Case Rep
Tan XHI, Yee HN, Kwan KWC, Tan AYH, Kok S, Tan MO.   +5 more
europepmc   +1 more source

Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study. [PDF]

Medicina (Kaunas), 2023
Yoon JH, Kim SE, Cho SH, Kim GA, Park Y, Park JW, Kang SH, Lee YS, Kim JH.   +8 more
europepmc   +1 more source

Phase IIB, Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID‐19

European Journal of Haematology, EarlyView.
ABSTRACT Introduction Endothelial dysfunction is key in COVID‐19 pathogenesis. This randomized, double‐blind phase IIb trial investigated continuous intravenous infusion of defibrotide in patients hospitalized with SARS‐CoV‐2 infection and respiratory failure.
Ruben Jara Rubio, Antonio José Martinez‐Mellado, Jonathan Kiwitt‐Cárdenas, José G. Clavel, Bartolomé García‐Perez, Pedro Castro, Maribel Diaz‐Ricart, Andrés Carrillo‐Alcaraz, Amparo López‐Bernús, Enrique Bernal Morell, Aychel Roura, Sonia Marín, Francisco‐José Ruiz‐López, Elena Solana‐Martinez, Domingo Martinez‐Baño, Carlos L. Albacete Moreno, Enriqueta Andreu Soler, Adrián Tellez Santoyo, Sara Fernández Méndez, Jose A. Noguera Velasco, Iria Cebreiros Lopez, Andrés Parrilla, Alberto Espuny‐Miró, David García‐Bernal, Miguel Blanquer, Andrés Sánchez‐Salinas, Francisca Iniesta, Cristina Hernandez Garcia, Manuel Muro, Alfredo Minguela Puras, Antonio Moreno‐Docón, Alberto M. Torres‐Cantero, Maria Munoz Garcia, Manuel Serrano, Massimo Iacobelli, Carmelo Carlo‐Stella, Lee‐Jen Wei, Paul G. Richardson, José M. Moraleda   +38 more
wiley   +1 more source

Risk factors for liver-related mortality of patients with hepatitis C virus after sustained virologic response to direct-acting antiviral agents. [PDF]

JGH Open, 2022
Hattori N, Ikeda H, Watanabe T, Satta Y, Ehira T, Suzuki T, Kiyokawa H, Nakahara K, Takahashi H, Matsunaga K, Matsumoto N, Yasuda H, Suzuki M, Itoh F, Tateishi K.   +14 more
europepmc   +1 more source